drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
A large body of evidence shows either directly or indirectly that small ions (from small molecules) are liberated into the gas phase through the ion evaporation mechanism, while larger ions (from folded proteins for instance) form by charged residue mechanism. A third model invoking combined charged residue-field emission has been proposed. Another model called chain ejection model (CEM) is proposed for disordered polymers (unfolded proteins). The ions observed by mass spectrometry may be quasimolecular ions created by the addition of a hydrogen cation and denoted [M + H]+, or of another cation such as sodium ion, [M + Na]+, or the removal of a hydrogen nucleus, [M − H]−. Multiply charged ions such as [M + nH]n+ are often observed. For large macromolecules, there can be many charge states, resulting in a characteristic charge state envelope. All these are even-electron ion species: electrons (alone) are not added or removed, unlike in some other ionization sources. The analytes are sometimes involved in electrochemical processes, leading to shifts of the corresponding peaks in the mass spectrum. This effect is demonstrated in the direct ionization of noble metals such as copper, silver and gold using electrospray. The efficiency of generating the gas phase ions for small molecules in ESI varies depending on the compound structure, the solvent used and instrumental parameters. The differences in ionization efficiency reach more than 1 million times.
Most branches and denominations of the Christian faith allow embalming. Some bodies within Eastern Orthodoxy profess an absolute ban on embalming except when required by law or other necessity, while others may discourage but do not prohibit it. In most Christian denominations, the decision on embalming is the preference of the deceased's family rather than for church policy or theological viewpoint. The Church of Jesus Christ of Latter-day Saints does not discourage or prohibit embalming. Often, due to the custom of church members dressing the deceased, embalming is given preference. Some Neopagans discourage embalming, believing it unnatural to disrupt the physical recycling of the body to the Earth. Members of the Bahá'í Faith are not embalmed. Instead, the body is washed and then placed in a cotton, linen, or silk shroud. Zoroastrians traditionally hold a type of sky burial within a structure known as a Tower of Silence in which the body is exposed to weathering and predation to dispose of the remains. Embalming the body is thus contrary to their funeral designs. Traditional Jewish law forbids embalming. Burial is to be done as soon as possible; preferably within 24 hours. Embalming is not a standard practice in Hinduism. The body is usually cremated as soon as possible, preferably within 24 hours, except when the offspring of the deceased need time to get to the location (in which case the body is refrigerated).
== Chemistry == The major chemical components from the pods are vanillin, vanillic acid, 4-hydroxybenzaldehyde and 4-hydroxybenzoic acid. Vanillin makes up 80% of the total aromatic compounds found in the pods, in contrast to the 50% content of Vanilla × tahitensis pods. Some of the other chemicals found in lesser amounts in the pods of Vanilla planifolia such as guaiacol, 4-methylguaiacol, acetovanilone, and vanillic alcohol also contribute to the perception of a vanilla flavor.Vanilla planifolia is notable for its role in vanilla production. The enzyme β-glucosidase is crucial in the release of vanillin during the curing process, which is essential for producing high-quality vanilla flavor.
A total of 51 cases of homozygotes or compound heterozygotes have been reported, most of them with double truncating MYBPC3 mutations and associated with severe cardiomyopathy, leading to heart failure and death within the first year of life.
Sources: en.wikipedia.org
Tina Ruth Coldham. Participation, Involvement and Engagement Advisor, NIHR. For services to Inclusive Patient and Public Involvement in Research. ShelleyJane Coleman. For services to the community in Plymouth, Devon. Robert John Collins. Founder, Pass It On Young Sports Voluntary Youth Organisation. For services to Young People and to Sport. Geraldine Constable. For services to the community in Hailsham and Eastbourne, East Sussex. Rev. Canon Diane Veronica Cookson. For services to St. Saviour's Parish Church and to the community in Stockport, Greater Manchester. Reginald John Cording. For services to the community in Barley, Hertfordshire. Jon-Paul Kitson Cornforth. For services to the community in Rotherham, South Yorkshire, particularly during Covid-19. Margaret Cortis. For voluntary and charitable services to the community in Truro, Cornwall. Robert David Cotterill. For services to Business and to the community in Derbyshire. Chico Cheikh Sadibou Coulibaly. Regional Manager Waterloo, South Western Railway. For services to the State Funeral of Her Majesty Queen Elizabeth II. Noel Desmond Cronin. Founder, Talking Pictures TV. For services to Television Broadcasting. Jill Elaine Crook. Director, Nursing, Professional and System Development, NHS England (South West). For services to Transforming Care, Learning Disability and Autism. David Cupples. For services to the community in County Tyrone. John Andrew Daley. For services to Young People and to the community in Sheffield, South Yorkshire. Anita Davenport-Brooks. Group Human Resources Manager, Lander Automotive.
Citrullination or deimination is the conversion of the amino acid arginine in a protein into the amino acid citrulline. Citrulline is not one of the 20 standard amino acids encoded by DNA in the genetic code. Instead, it is the result of a post-translational modification. Citrullination is distinct from the formation of the free amino acid citrulline as part of the urea cycle or as a byproduct of enzymes of the nitric oxide synthase family. Enzymes called arginine deiminases catalyze the deimination of free arginine, while protein arginine deiminases or peptidylarginine deiminases (PADs) replace the primary ketimine group by a ketone group. Arginine is positively charged at a neutral pH, whereas citrulline has no net charge. This increases the hydrophobicity of the protein, which can lead to changes in protein folding, affecting the structure and function. The immune system can attack citrullinated proteins, leading to autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Fibrin and fibrinogen may be favored sites for arginine deimination within rheumatoid joints. Test for presence of anti-citrullinated protein antibodies are highly specific (88–96%) for rheumatoid arthritis, about as sensitive as rheumatoid factor (70–78%) for diagnosis of RA, and are detectable from even before the onset of clinical disease. Citrullinated vimentin may be an autoantigen in rheumatoid arthritis and other autoimmune diseases, and is used to study rheumatoid arthritis.
4He* → n + 3He + 3.3 MeV (ratio=50%) 4He* → p + 3H + 4.0 MeV (ratio=50%) 4He* → 4He + γ + 24 MeV (ratio=10−6) Only about one in a million of the intermediaries take the third pathway, making its products very rare compared to the other paths. This result is consistent with the predictions of the Bohr model. If 1 watt (6.242 × 1018 eV/s) were produced from ~2.2575 × 1011 deuteron fusions per second, with the known branching ratios, the resulting neutrons and tritium (3H) would be easily measured. Some researchers reported detecting 4He but without the expected neutron or tritium production; such a result would require branching ratios strongly favouring the third pathway, with the actual rates of the first two pathways lower by at least five orders of magnitude than observations from other experiments, directly contradicting both theoretically predicted and observed branching probabilities. Those reports of 4He production did not include detection of gamma rays, which would require the third pathway to have been changed somehow so that gamma rays are no longer emitted. The known rate of the decay process together with the inter-atomic spacing in a metallic crystal makes heat transfer of the 24 MeV excess energy into the host metal lattice prior to the intermediary's decay inexplicable by conventional understandings of momentum and energy transfer, and even then there would be measurable levels of radiation. Also, experiments indicate that the ratios of deuterium fusion remain constant at different energies.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.